Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

It is a fictional representation created for illustrative purposes only. EU antitrust regulators are soliciting feedback from ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

The Series D financing will support the clinical development of two ADCs.

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

Ginkgo Bioworks Holdings, Inc. ( (DNA)) has released its Q3 earnings ... including signing new deals with Novo Nordisk and Merck, and making strides in cost reduction and site consolidation.

BRUSSELS/LONDON (Reuters) - EU antitrust regulators have asked pharma rivals and customers for feedback in four business ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...